For Providers

At Karius, we are committed to diagnostic stewardship, which means supporting you in identifying the right patient, right test, and right time to use Karius testing solutions.

Who We Are

Karius is a clinical metagenomics company focused on helping to elevate patient care through microbial insights. We are a team of infectious disease experts, including medical directors and medical science liaisons, who are committed to patients, research, and advancing diagnostic science.

What We Do

Karius testing solutions detect pathogens by leveraging microbial cell-free DNA (mcfDNA). As microbes turn over, they shed genomic fragments in the body, leaving behind traces that hold critical clinical insights. Using metagenomic sequencing and artificial intelligence, we identify, analyze, and report these signals.

Our Products

Broad Detection of Pathogens Throughout the Body

Karius Spectrum is a blood test based on metagenomic sequencing of plasma microbial cell-free DNA that can detect over 1,000 pathogens associated with deep-seated and difficult-to-diagnose systemic infections caused by fungi, bacteria, parasites, and DNA viruses.

Tab Image

Patient Populations

The main clinical application for our testing solutions is to help detect infections in immunocompromise patients. However, our solutions have shown also applicability and clinical utility in immunocompetent patients across a variety of diagnostic applications.1,2

Hematopoietic  Cell Transplantation

Hematopoietic Cell Transplantation

Solid Organ  Transplantation

Solid Organ Transplantation

Other Immunocompromised Hosts

Other Immunocompromised Hosts

Featured Guidelines & Evidence

Scroll through to read recent publications, guidelines, and definitions that feature metagenomic sequencing of microbial cell-free DNA.

Metagenomic Sequencing Featured in ASTCT Guidelines for Non-Aspergillus Invasive Mold Infections

Metagenomic Sequencing Featured in ASTCT Guidelines for Non-Aspergillus Invasive Mold Infections

ASTCT Guideline Highlights the Karius Spectrum test for infection diagnosis in patients who have undergone hematopoietic stem cell transplantation.

View Publication
Metagenomic sequencing for Solid Organ Transplant Recipients per AST Consensus Guidance

Metagenomic sequencing for Solid Organ Transplant Recipients per AST Consensus Guidance

Per consensus guidance sponsored by American Society of Transplantation: Plasma-based NGS may be useful when a focal site of infection cannot be accessed for sampling.

View Publication
Metagenomic Sequencing Featured in 2023 Duke-ISCVID Criteria for Infective Endocarditis

Metagenomic Sequencing Featured in 2023 Duke-ISCVID Criteria for Infective Endocarditis

First time inclusion of hypothesis-free metagenomic testing, such as the Karius Spectrum test for the rapid identification of hard-to-detect pathogens.

View Publication

Have a question about our products?

We are here to help. Fill out the contact form below and one of our medical specialists will be in touch with you.

References

  1. Farnaes L, et al. Diagn Microbiol Infect Dis. 2019;94(2):188-191.
  2. Ho EC, et al. Clin Infect Dis. 2024;79(6):1487-1494. doi:10.1093/cid/ciae439
  3. Hill JA, et al. Open Forum Infect Dis. 2024;11(1):ofad616.
  4. Schuster MG, et al. Open Forum Infect Dis. 2017;4(2):ofx050
  5. Zembower TR. Cancer Treat Res. 2014;161:43-89.
  6. Singh N, et al. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 308, 3672-3697.e4.
  7. Dulek DE, Mueller NJ. Clin Transplant. 2019;33(9):e13545.
  8. Park S, et al. Open Forum Infect Dis. 2025. doi:10.1093/ofid/ofaf001.
  9. Everhart J, Henshaw NG. Infect Dis Clin North Am. 2023;37(3):495-513.
  10. Kotton CN, et al. Transplantation. 2018;102(6):900-931.
  11. Foong et al. Open Forum Infectious Diseases, 2022; ofac652
  12. Francisco D, et al. Antimicrob Steward Healthc Epidemiol. 2023 Feb 17;3(1):e31.
  13. Shah JR, et al. Ther Adv Infect Dis. 2024;11:20499361241308643. Published 2024 Dec 23.
  14. Freeman Weiss Z et al. J Fungi (Basel). 2021 Feb 9;7(2):127.
  15. Lu Y, et al. Intern Med. 2011;50(22):2783-91. Epub 2011 Nov 15.
  16. Leeflang MMG, et al. Cochrane Database Syst Rev. 2015 Dec 30; 2015(12): CD007394.
  17. Caliendo AM, et al. Clin Infect Dis. 2013;57 Suppl 3:S139-170
  18. Fung M, et al. Open Forum Infect Dis. 2018;5(12): ofy301
  19. Yadegarynia D, et al. Clin Infect Dis. 2003;37(8):1144-1145
  20. Bauer PR et al. Eur Respir J. 2019;54(1)
  21. Batra S et al. Pediatr Blood Cancer. 2015;62(9):1579-1586
  22. Hofmeister CC et al. Bone Marrow Transplant. 2006;38(10):693-698
  23. Patel NR et al. Chest. 2005;127(4):1388-1396
  24. Chang H et al. Medicine (Baltimore) 1976;55(3):259–268
  25. Hersh E et al. JAMA. 1965;193:105–109
  26. Homsi J et al. Support Care Cancer. 2000;8(6):487–492
  27. Norgaard M et al. Clin Microbiol Infect. 2006;12(3):217–223